Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rho GTPase activating protein 26 | 0.656 | 0.500 | 1.00 |
|
disease | 0.340 | None | 0.750 | 0 | 0 | 2006 | 2014 | ||||||||
|
BCL6 corepressor | 0.471 | 0.808 | 1.00 |
|
disease | 0.370 | None | 1.000 | 0 | 0 | 2011 | 2019 | ||||||||
|
BRCA1 interacting protein C-terminal helicase 1 | 0.507 | 0.731 | 6.2E-17 |
|
disease | 0.500 | strong | 1.000 | 0 | 0 | 2017 | 2017 | ||||||||
|
Cbl proto-oncogene | 0.527 | 0.769 | 6.1E-04 |
|
disease | 0.500 | None | 1.000 | 0 | 0 | 2003 | 2019 | ||||||||
|
Cbl proto-oncogene B | 0.691 | 0.423 | 1.00 |
|
disease | 0.310 | None | 1.000 | 0 | 0 | 2007 | 2007 | ||||||||
|
Cbl proto-oncogene C | 0.821 | 0.192 | 4.2E-11 |
|
disease | 0.300 | None | 0 | 0 | |||||||||||
|
CCAAT enhancer binding protein alpha | 0.496 | 0.692 | 0.55 |
|
disease | 1.000 | definitive | 0.985 | 0 | 0 | 1992 | 2020 | ||||||||
|
CREB binding protein | 0.428 | 0.808 | 1.00 |
|
disease | 0.600 | None | 1.000 | 0 | 0 | 1996 | 2019 | ||||||||
|
colony stimulating factor 3 receptor | 0.550 | 0.692 | 1.5E-10 |
|
disease | 0.500 | None | 0.980 | 0 | 0 | 1995 | 2019 | ||||||||
|
cut like homeobox 1 | 0.465 | 0.846 | 1.00 |
|
disease | 0.330 | None | 0.667 | 0 | 0 | 1993 | 2019 | ||||||||
|
DNA methyltransferase 3 alpha | 0.445 | 0.846 | 7.4E-39 |
|
disease | 0.800 | limited | 0.955 | 0 | 0 | 2009 | 2019 | ||||||||
|
E1A binding protein p300 | 0.459 | 0.846 | 1.00 |
|
disease | 0.360 | None | 1.000 | 0 | 0 | 1997 | 2013 | ||||||||
|
ETS variant transcription factor 6 | 0.477 | 0.731 | 0.97 |
|
disease | 0.800 | strong | 0.981 | 0 | 0 | 1995 | 2019 | ||||||||
|
FA complementation group A | 0.505 | 0.731 | 1.6E-68 |
|
disease | 0.530 | strong | 1.000 | 0 | 0 | 2002 | 2017 | ||||||||
|
FA complementation group C | 0.507 | 0.808 | 2.8E-13 |
|
disease | 0.520 | strong | 1.000 | 0 | 0 | 2003 | 2016 | ||||||||
|
FA complementation group D2 | 0.479 | 0.885 | 1.1E-30 |
|
disease | 0.510 | strong | 1.000 | 0 | 0 | 2005 | 2017 | ||||||||
|
FA complementation group E | 0.553 | 0.808 | 1.5E-06 |
|
disease | 0.500 | strong | 1.000 | 0 | 0 | 2017 | 2017 | ||||||||
|
FA complementation group F | 0.535 | 0.731 | 0.46 |
|
disease | 0.510 | strong | 1.000 | 0 | 0 | 2003 | 2017 | ||||||||
|
FA complementation group G | 0.556 | 0.769 | 2.5E-14 |
|
disease | 0.510 | strong | 1.000 | 0 | 0 | 2016 | 2017 | ||||||||
|
fms related receptor tyrosine kinase 3 | 0.462 | 0.654 | 0.61 |
|
disease | 1.000 | None | 0.985 | 0 | 0 | 1992 | 2020 | ||||||||
|
GATA binding protein 2 | 0.496 | 0.654 | 0.98 |
|
disease | 0.800 | None | 0.974 | 0 | 0 | 1994 | 2020 | ||||||||
|
HRas proto-oncogene, GTPase | 0.378 | 0.885 | 8.0E-02 |
|
disease | 0.500 | None | 0.833 | 0 | 0 | 1987 | 2016 | ||||||||
|
isocitrate dehydrogenase (NADP(+)) 1 | 0.424 | 0.808 | 2.6E-12 |
|
disease | 0.700 | None | 0.969 | 0 | 0 | 2009 | 2020 | ||||||||
|
isocitrate dehydrogenase (NADP(+)) 2 | 0.434 | 0.808 | 0.88 |
|
disease | 0.700 | None | 0.961 | 0 | 0 | 2010 | 2019 | ||||||||
|
Janus kinase 1 | 0.474 | 0.769 | 1.00 |
|
disease | 0.430 | None | 1.000 | 0 | 0 | 2008 | 2018 |